Trial Profile
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2025
Price :
$35
*
At a glance
- Drugs ARX 788 (Primary) ; Cemiplimab (Primary) ; Dostarlimab (Primary) ; Durvalumab (Primary) ; Encequidar+paclitaxel (Primary) ; Endoxifen (Primary) ; Evorpacept (Primary) ; Fianlimab (Primary) ; Ganetespib (Primary) ; Ganitumab (Primary) ; Ladiratuzumab-Vedotin (Primary) ; Lasofoxifene (Primary) ; Letrozole (Primary) ; MK 2206 (Primary) ; Nelitolimod (Primary) ; Neratinib (Primary) ; Olaparib (Primary) ; Patritumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Talazoparib (Primary) ; Trastuzumab (Primary) ; Trastuzumab-duocarmazine (Primary) ; Trebananib (Primary) ; Trilaciclib (Primary) ; Tucatinib (Primary) ; Veliparib (Primary) ; Vepdegestrant (Primary) ; Carboplatin; Conatumumab; Cyclophosphamide; Datopotamab deruxtecan; Doxorubicin; Figitumumab; Metformin; Paclitaxel; Trastuzumab emtansine
- Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms I-SPY; I-SPY-2; I-SPY2; SMART; SURMOUNT
Most Recent Events
- 14 May 2025 According to Atossa Therapeutics media release, the company is actively enrolling participants into an additional cohort testing (Z)-endoxifen at a 40 mg daily dose and in combination with abemaciclib, with and without ovarian function suppression. And, the top-line data from these arms are expected beginning in 2026.
- 14 May 2025 Results published in the Atossa Therapeutics media release
- 01 May 2025 Results published in the Annals of Surgical Oncology.